Treatment Overview

The ALL treatment that a patient receives depends on a number of factors, for example, age, other co-existing medical conditions and the specific type of ALL that the person is suffering from.

Patients who are “fit” (no prior significant medical conditions) and under 70 years old are usually given intravenous (IV) chemotherapy, which requires hospitalisation for 3–4 weeks (or more in case of treatment-related complications). Older and/or more “frail” patients (patients with serious prior medical conditions) may be given other treatment options, such as subcutaneous (applied under the skin) or oral (taken by the mouth) therapies.

Watch the videos in this section to learn more about various treatment options available for ALL and to gain a better understanding of how to best approach your doctors with treatment questions.

 

Videos

Does the Clinical Trial Process Need an Extreme Makeover?

In this MythBusters program, patient advocate Jim Omel and Dr. Michael Thompson examine barriers patients may face and discuss the safety and quality of clinical trial care. Does the process need a makeover? Watch now to find out more.

Published:

Sugar Pill Myth: What Am I Really Getting in a Clinical Trial?

One barrier to clinical trial enrollment is the myth that patients might receive a sugar pill and get no treatment at all. Watch as Dr. Heather Wakelee lays out the clinical trial facts.

Published:

Inside the First FDA-Approved CAR-T Cell Therapy

ALL patients who haven’t responded to standard care have new options on the horizon, including a type of immunotherapy called CAR T-cell therapy. Learn more from Dr. Michael Deininger.

Published:

Capacidad de decisión del paciente durante el tratamiento

El paciente, siempre y cuando sus facultades mentales estén en buenas condiciones, es el último responsable a la hora de decidir el tratamiento a recibir.

Published:

Akute lymphatische Leukämie: Behandlung nach der Diagnose

Prof. Dr. med. Dieter Hoelzer vom Universitätsklinikum Frankfurt, Frankfurt am Main, Deutschland bespricht die Behandlung der akuten lymphatischen Leukämie (ALL).

Published:

Was Patienten mit akuter lymphatischen Leukämie (ALL) während ihrer Behandlung beachten sollen

Prof. Dr. med. Dieter Hoelzer vom Universitätsklinikum Frankfurt, Frankfurt am Main, Deutschland erklärt was Patienten mit akuter lymphatischen Leukämie (ALL) während ihrer Behandlung beachten müssen.

Published:

Neue Behandlungsmöglichkeiten für die akute lymphatische Leukämie

Prof. Dr. med. Dieter Hoelzer vom Universitätsklinikum Frankfurt, Frankfurt am Main, Deutschland bespricht neue Behandlungsmöglichkeiten für Patienten mit akuter lymphatischen Leukämie (ALL).

Published:

Les derniers progrès observés dans le traitement de la leucémie

Elias Jabbour, professeur au MD Anderson Cancer Center de l'université du Texas explique que les traitements ciblés ont permis d’observer des améliorations dans le traitement de la leucémie.

Published:

Sur quels critères est établi le traitement d’une leucémie ?

Elias Jabbour, professeur au MD Anderson Cancer Center de l'université du Texas décrit les étapes nécessaires pour pouvoir diagnostiquer une leucémie.

Published:

Showing 9 of 39 programs
Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on April 3, 2017